View Older Stories View More Recent Stories
-
Elektrofi Announces Oversubscribed $112.25 Million Series C Financing to Establish Commercial-Scale GMP Manufacturing Capacity & Accelerate Clinical Development Across its Growing Portfolio of Par
-
Evommune Announces $115 Million Series C Financing to Accelerate Advancement of Clinical-Stage Pipeline Addressing Chronic Inflammatory Diseases
-
Aerovate Therapeutics (AVTE) and Jade Biosciences Announce Merger Agreement
-
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
-
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock
-
Eledon Pharmaceuticals (ELDN) Prices $85M Offering at $3.65/sh
-
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
-
Monopar Therapeutics (MNPR) Prices $19.2M Share Offering at $16.25/sh
-
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
-
AbbVie (ABBV) Acquires Aliada Therapeutics
-
AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience Pipeline
-
Alpha-9 Oncology Inc. Announces $175 Million Oversubscribed Series C Financing to Advance Robust Clinical Pipeline of Radiopharmaceuticals
-
Form SC 13D/A Tyra Biosciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Janux Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Be Bio Announces $82 Million Financing and Transition to Clinical Stage Company
-
Dignify Therapeutics Selected as a Praxis SCI Accelerate Company
-
Dignify to highlight recent accomplishments at the 2024 BIO Investor Forum
-
Dignify Therapeutics welcomes leading healthcare entrepreneurs Howard Palefsky and Neil Kurtz, MD to its Board of Directors
-
Adcendo Announces US FDA Clearance of IND Application for Phase I/II First-in-Human ADCElerate-01 Trial of ADCE-D01 (uPARAP Receptor Targeting ADC) Trial in Patients With Metastatic and/or Unresectabl
-
Form SC 13G BioAge Labs, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Wave Life Sciences Ltd. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Dignify Therapeutics to Participate in the BIO Investor Forum, October 2024
-
Be Biopharma Announces Preclinical Data for Novel Engineered B Cell Medicine for the Potential Treatment of Hypophosphatasia
-
Superluminal Medicines Announces Formation of Scientific Advisory Board
-
GentiBio Appoints Mark Bach, M.D., Ph.D., as Chief Medical Officer
-
AKTIS ONCOLOGY ANNOUNCES $175 MILLION OVERSUBSCRIBED SERIES B FINANCING TO FURTHER ADVANCE ITS PROPRIETARY RADIOPHARMACEUTICAL PIPELINE
-
Form SC 13D Bicara Therapeutics Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Cidara Therapeutics (CDTX) Announces Scientific Advisory Board with Infectious Disease Experts
-
Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts
-
Eyconis, Inc. Announces Appointment of Dr. Mark J. Bachleda as Chief Executive Officer and Member of the Board of Directors
-
Dignify Therapeutics awarded two new research grants from the National Institutes of Health (NIH)
-
RA Capital Launches Structured Capital Solutions
-
Form SC 13D/A Janux Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G/A Fulcrum Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Adela Announces Clinical Validation Results for Head & Neck Cancer MRD Test Simultaneously Published in Annals of Oncology and Presented at ESMO 2024
-
Superluminal Medicines Closes $120 Million Series A Round
-
Vesta Healthcare Raises $65 Million in Financing to Propel Growth
-
Jnana Therapeutics Presents New Positive Data from Phase 1/2 Study of JNT-517 in Individuals with Phenylketonuria – Results Support Planned Pivotal Study in Early 2025
-
Form SC 13D/A Artiva Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Horizon Technology Finance (HRZN) Provides $35 Million Venture Loan Facility to Vesta Healthcare
-
Horizon Technology Finance Provides $35 Million Venture Loan Facility to Vesta Healthcare
-
Form N-PX RA CAPITAL MANAGEMENT, For: Jun 30
-
Navigator Medicines Announces $100 Million Series A Financing and In-Licensing of NAV-240, a Potential Best-in-Class Anti-OX40L and Anti-TNFα Bispecific Antibody Therapeutic for Autoimmune Diseases
-
Form SC 13G/A Fulcrum Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Avalo Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Adcendo ApS and Multitude Therapeutics Inc. Announce Global Development and Commercialization Agreement on First-in-class ADC Drug Candidate Targeting Tissue Factor
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Jun 30
-
Form SC 13G/A AN2 Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
-
Form SC 13G Adagio Medical Holdings, Filed by: RA CAPITAL MANAGEMENT, L.P.
